Advertisement

Intensive Care Medicine

, Volume 45, Issue 4, pp 512–515 | Cite as

What’s new on emerging resistant Candida species

  • Andrea CortegianiEmail author
  • Giovanni Misseri
  • Anuradha Chowdhary
What's New in Intensive Care

Introduction

Accounting for more than 400,000 annual cases worldwide, with an incidence from 0.24 to 34.3 patients/1000 ICU admissions and mortality that approaches 40%, Candida spp. constitute the third or fourth most common cause of healthcare-related infections worldwide [1]. Although C. albicans remains the main causative pathogen, the increasing isolations of non-albicans Candida spp. resistant to first- and second-line antifungals (namely, fluconazole and echinocandins) in nosocomial infections is concerning. Resistance to azoles remains uncommon in C. albicans (< 5%), but it is more prevalent in C. glabrata (4–16%), C. parapsilosis (4–10%), and C. tropicalis (4–9%) [2]. Acquired resistance following echinocandin exposure appears to be on the rise, and the emergence of multi-resistant species among Candida glabrata and the novel pathogen Candida auris poses a serious threat to critically ill patients.

Echinocandin-resistant Candida glabrata

Variable rates of acquired echinocandin...

Notes

Compliance with ethical standards

Conflicts of interest

The authors declare no conflict of interest.

References

  1. 1.
    Bassetti M, Garnacho-Montero J, Calandra T et al (2017) Intensive Care medicine research agenda on invasive fungal infection in critically ill patients. Intensive Care Med 43:1225–1238.  https://doi.org/10.1007/s00134-017-4731-2 CrossRefGoogle Scholar
  2. 2.
    Maubon D, Garnaud C, Calandra T et al (2014) Resistance of Candida spp. to antifungal drugs in the ICU: where are we now? Intensive Care Med 40:1241–1255.  https://doi.org/10.1007/s00134-014-3404-7 CrossRefGoogle Scholar
  3. 3.
    Alexander BD, Johnson MD, Pfeiffer CD et al (2013) Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 56:1724–1732.  https://doi.org/10.1093/cid/cit136 CrossRefGoogle Scholar
  4. 4.
    Pfaller MA, Castanheira M, Lockhart SR et al (2012) Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol 50:1199–1203.  https://doi.org/10.1128/JCM.06112-11 CrossRefGoogle Scholar
  5. 5.
    Pham CD, Iqbal N, Bolden CB et al (2014) Role of FKS mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance. Antimicrob Agents Chemother 58:4690–4696.  https://doi.org/10.1128/AAC.03255-14 CrossRefGoogle Scholar
  6. 6.
    Klotz U, Schmidt D, Willinger B et al (2016) Echinocandin resistance and population structure of invasive Candida glabrata isolates from two university hospitals in Germany and Austria. Mycoses 59:312–318.  https://doi.org/10.1111/myc.12472 CrossRefGoogle Scholar
  7. 7.
    Marcos-Zambrano LJ, Escribano P, Sanchez C et al (2014) Antifungal resistance to fluconazole and echinocandins is not emerging in yeast isolates causing fungemia in a Spanish tertiary care center. Antimicrob Agents Chemother 58:4565–4572.  https://doi.org/10.1128/AAC.02670-14 CrossRefGoogle Scholar
  8. 8.
    Delliere S, Healey K, Gits-Muselli M et al (2016) Fluconazole and echinocandin resistance of candida glabrata correlates better with antifungal drug exposure rather than with MSH2 mutator genotype in a french cohort of patients harboring low rates of resistance. Front Microbiol 7:2038.  https://doi.org/10.3389/fmicb.2016.02038 CrossRefGoogle Scholar
  9. 9.
    Scapaticci M, Bartolini A, Del Chierico F et al (2018) Phenotypic typing and epidemiological survey of antifungal resistance of Candida species detected in clinical samples of Italian patients in a 17 months’ period. Germs 8:58–66.  https://doi.org/10.18683/germs.2018.1132 CrossRefGoogle Scholar
  10. 10.
    Castanheira M (2018) Fungemia surveillance in Denmark demonstrates emergence of non-albicans Candida species and higher antifungal usage and resistance rates than in other nations. J Clin Microbiol 56:e01907–e01917.  https://doi.org/10.1128/JCM.01907-17 CrossRefGoogle Scholar
  11. 11.
    Singh A, Healey KR, Yadav P et al (2018) Absence of azole or echinocandin resistance in Candida glabrata isolates in India despite background prevalence of strains with defects in the DNA mismatch repair pathway. Antimicrob Agents Chemother.  https://doi.org/10.1128/AAC.00195-18 Google Scholar
  12. 12.
    Perlin DS (2015) Echinocandin resistance in Candida. Clin Infect Dis 61(Suppl 6):S612–S617.  https://doi.org/10.1093/cid/civ791 CrossRefGoogle Scholar
  13. 13.
    Arendrup MC, Patterson TF (2017) Multidrug-resistant Candida: epidemiology, molecular mechanisms, and treatment. J Infect Dis 216:S445–S451.  https://doi.org/10.1093/infdis/jix131 CrossRefGoogle Scholar
  14. 14.
    Shields RK, Nguyen MH, Clancy CJ (2015) Clinical perspectives on echinocandin resistance among Candida species. Curr Opin Infect Dis 28:514–522CrossRefGoogle Scholar
  15. 15.
    Schell WA, Jones AM, Borroto-Esoda K, Alexander BD (2017) Antifungal activity of SCY-078 and standard antifungal agents against 178 clinical isolates of resistant and susceptible Candida species. Antimicrob Agents Chemother 62:e00195-18.  https://doi.org/10.1128/AAC.01102-17 Google Scholar
  16. 16.
    Kohlenberg A, Struelens MJ, Monnet DL, Plachouras D (2018) Candida auris: epidemiological situation, laboratory capacity and preparedness in European Union and European Economic Area countries, 2013 to 2017. Euro Surveill.  https://doi.org/10.2807/1560-7917.ES.2018.23.13.18-00136 Google Scholar
  17. 17.
    Chowdhary A, Sharma C, Meis JF (2017) Candida auris: a rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathog 13:e1006290.  https://doi.org/10.1371/journal.ppat.1006290 CrossRefGoogle Scholar
  18. 18.
  19. 19.
    Lockhart SR, Etienne KA, Vallabhaneni S et al (2017) Simultaneous emergence of multidrug-resistant candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis 64:134–140.  https://doi.org/10.1093/cid/ciw691 CrossRefGoogle Scholar
  20. 20.
    Ku TSN, Walraven CJ, Lee SA (2018) Candida auris: disinfectants and implications for infection control. Front Microbiol 9:726.  https://doi.org/10.3389/fmicb.2018.00726 CrossRefGoogle Scholar
  21. 21.
    Kordalewska M, Lee A, Park S et al (2018) Understanding echinocandin resistance in the emerging pathogen Candida auris. Antimicrob Agents Chemother 62:e00238-18.  https://doi.org/10.1128/AAC.00238-18 CrossRefGoogle Scholar
  22. 22.
    Chowdhary A, Prakash A, Sharma C et al (2018) A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009–2017) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance. J Antimicrob Chemother 73:891–899.  https://doi.org/10.1093/jac/dkx480 CrossRefGoogle Scholar
  23. 23.
    Hager CL, Larkin EL, Long LA, Ghannoum MA (2018) Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model. J Antimicrob Chemother 73:2085–2088.  https://doi.org/10.1093/jac/dky153 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature and ESICM 2018

Authors and Affiliations

  1. 1.Department of Biopathology and Medical Biotechnologies (DIBIMED), Section of Anesthesia Analgesia Intensive Care and Emergency, Policlinico Paolo GiacconeUniversity of PalermoPalermoItaly
  2. 2.Department of Medical Mycology, Vallabhbhai Patel Chest InstituteUniversity of DelhiDelhiIndia

Personalised recommendations